Detail akcie Vertex Pharma online

Business Summary: Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Vertex Pharmaceuticals Inc revenues increased 3% to $2.77B. Net income decreased 41% to $646.3M. Revenues reflect TRIKAFTA segment increase of 2% to $2.54B, United States segment increase of 9% to $1.65B, Other segment increase of 38% to $280.1M. Net income was offset by Research and development Expenses - Bala increase of 41% to $630.6M (expense), Sales.